Steagall Paulo V M, Monteiro Beatriz P, Lavoie Anne-Marie, Troncy Eric
Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, QC, Canada
Department of Biomedical Sciences, Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, QC, Canada.
J Feline Med Surg. 2015 Dec;17(12):1061-4. doi: 10.1177/1098612X14564710. Epub 2015 Jan 8.
The aim of this study was to evaluate the potential thermal antinociceptive effects of oral administration of a single dose of codeine in cats compared with positive (buprenorphine) and negative (saline 0.9%) controls.
Six adult healthy cats weighing 5.14 ± 0.6 kg were used. Skin temperature and thermal thresholds (TTs) were evaluated using a wireless device (Topcat Metrology) at baseline, 0.5, 1, 3, 6 and 10 h after treatment. In period 1, TTs were evaluated after subcutaneous administration of saline 0.9%. In period 2, cats were administered either oral codeine (10 mg total, 2.0 ± 0.2 mg/kg) or buccal buprenorphine (0.04 mg/kg) in a cross-over, blinded study design. Half of the volume of buprenorphine was administered into each cheek pouch. Δ TT (difference between TTs after and before treatment) was used for data comparison. Mean ± SD data were analyzed using one-way ANOVA followed by Dunnett's or Tukey's test when appropriate (P <0.05).
Adverse effects did not occur in any group. Skin temperature was not different between groups nor over time. Temporal changes in TTs were not observed after saline or codeine. Buprenorphine increased Δ TT at 3 h (2.7 ± 3.3°C) when compared with baseline or saline (P <0.05). For buprenorphine, TTs were not >47.6°C at any time point in four cats. The mean highest temperature recorded in the two other cats in that group was 54.5 and 52.8°C at 3 h.
At the dose administered, codeine did not produce thermal antinociception. Mild increases in TT after buccal buprenorphine might be related to the first-pass effect after drug swallowing, drug spillage during administration and/or individual variability. These factors should be taken in to consideration when administering buprenorphine by this route in the clinical setting.
本研究旨在评估与阳性对照（丁丙诺啡）和阴性对照（0.9%生理盐水）相比，猫口服单剂量可待因的潜在热镇痛作用。
使用6只体重为5.14±0.6千克的成年健康猫。在治疗前、治疗后0.5、1、3、6和10小时，使用无线设备（Topcat Metrology）评估皮肤温度和热阈值（TTs）。在第1阶段，皮下注射0.9%生理盐水后评估TTs。在第2阶段，采用交叉、双盲研究设计，给猫口服可待因（总量10毫克，2.0±0.2毫克/千克）或口腔颊部给予丁丙诺啡（0.04毫克/千克）。丁丙诺啡的一半剂量注入每个颊囊。使用ΔTT（治疗后和治疗前TTs的差值）进行数据比较。均值±标准差数据采用单因素方差分析，随后在适当情况下采用Dunnett检验或Tukey检验（P<0.05）。
任何组均未出现不良反应。各组之间以及不同时间的皮肤温度均无差异。注射生理盐水或可待因后未观察到TTs的时间变化。与基线或生理盐水相比，丁丙诺啡在3小时时使ΔTT升高（2.7±3.3°C）（P<0.05）。对于丁丙诺啡，4只猫在任何时间点的TTs均未超过47.6°C。该组另外2只猫在3小时时记录的平均最高温度分别为54.5°C和52.8°C。
在所给予的剂量下，可待因未产生热镇痛作用。口腔颊部给予丁丙诺啡后TTs的轻度升高可能与药物吞咽后的首过效应、给药过程中的药物溢出和/或个体差异有关。在临床环境中通过该途径给予丁丙诺啡时应考虑这些因素。
